
PFE News
Pfizer Inc.
$29.39
-$0.06(-0.20%)
76
Overall
100
Value
83
Tech
47
Quality
Market Cap
$167.52B
Volume
48.32M
52W Range
$23.62 - $31.44
Target Price
$29.71
PFE news: the latest Pfizer Inc. headlines, press releases and market updates, newest first.
Latest PFE News
- Pantera Minerals Issues 660,502 Shares for ServicesTipRanks Australian Auto-Generated Newsdesk · Nov 6, 2026
- Pantera Minerals Seeks Quotation of 660,502 SharesTipRanks Australian Auto-Generated Newsdesk · Nov 6, 2026
- Pantera Minerals Shareholders Approve AGM ResolutionsTipRanks Australian Auto-Generated Newsdesk · Nov 6, 2026
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Nuvectis Pharma (NVCT) and Pfizer (PFE)TipRanks Newsroom · Nov 5, 2026
- Pfizer Advances Monthly Obesity Drug Study as Investors Watch for a Competitive EdgeTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 5, 2026
- Analysts Are Bullish on These Healthcare Stocks: Sotera Health (SHC), Pfizer (PFE)TipRanks Newsroom · Nov 4, 2026
- Analysts Offer Insights on Healthcare Companies: Lifecore Biomedical (LFCR), Addus Homecare (ADUS) and Pfizer (PFE)TipRanks Newsroom · Nov 4, 2026
- RBC Capital Keeps Their Hold Rating on Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Nov 4, 2026
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Pfizer (PFE) and Harmony Biosciences Holdings (HRMY)TipRanks Newsroom · Nov 4, 2026
- Pfizer’s New Cancer Study Keeps Investors Watching the PipelineTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 3, 2026
- The Week That Was, The Week Ahead: Macro and Markets, November 1Ran Melamed · Nov 1, 2026
- Pfizer Targets Severe Asthma With Tilrekimig: What Investors Should WatchTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 30, 2026
- Pfizer Adds New Alzheimer’s Candidate to Early-Stage Pipeline With PF-08161842 TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 30, 2026
- Pfizer’s Lorlatinib Gains Real World Momentum in China Lung Cancer StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 30, 2026
- Pfizer Targets PIK3CA-Mutated Cancers With New Phase 1 Study: What Investors Should WatchTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 28, 2026
- Pantera Minerals Issues Shares to Fund New Project AcquisitionTipRanks Australian Auto-Generated Newsdesk · Oct 28, 2026
- RBC Capital Sticks to Their Hold Rating for Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Oct 28, 2026
- Pantera Minerals Secures Full Ownership of Corona Gold Project in WATipRanks Australian Auto-Generated Newsdesk · Oct 27, 2026
- Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)Newswire TipRanks · Oct 26, 2026
- Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial FailureRan Melamed · Oct 25, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PFE | $29.39 | -0.2% | 48.32M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |